Ereshefsky, Larry

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

May, P. C., Willis, B. A., Lowe, S. L., Dean, R. A., Monk, S. A., Cocke, P. J., Audia, J. E., Boggs, L. N., Borders, A. R., Brier, R. A., et al. (2015) · The Journal of Neuroscience

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 206

Clinical Pharmacokinetics of the Depot Antipsychotics

Jann, M. W., Ereshefsky, L., & Saklad, S. R. (1985) · Clinical Pharmacokinetics

Schizophrenia research and treatmentPharmacogenetics and Drug Metabolism

Cited by 125

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

Fava, M., Johe, K., Ereshefsky, L., Gertsik, L. G., English, B. A., Bilello, J. A., Thurmond, L. M., Johnstone, J., Dickerson, B. C., Makris, N., et al. (2016) · Molecular Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 45